Shegos Cameron Joseph, Chaudhry Arooj Fatima
Saint James School of Medicine, Park Ridge, IL, USA.
Ann Jt. 2022 Jul 15;7:26. doi: 10.21037/aoj-21-16. eCollection 2022.
To describe and discuss the purposed mechanism of mesenchymal stem cells (MSCs) and their effect as a potential therapeutic in osteoarthritis (OA).
OA is a chronic, degenerative joint disease affecting millions worldwide. Traditional management, including physical therapy, anti-inflammatories, intra-articular injections, and surgical procedures are directed towards symptom control rather than disease modification. In light of a better understanding that low-grade inflammation disrupts articular cartilage homeostasis in OA, application of MSCs as a form of regenerative medicine has emerged with the goal to provide symptomatic relief as well as reverse the articular cartilage damage seen in OA.
PubMed was searched using terms 'osteoarthritis', 'mesenchymal stem cell', 'regenerative medicine', 'chondrocyte', and 'articular cartilage' available from 2006 through May 2021.
The use of MSC therapy for articular cartilage regeneration through direct tissue growth, differentiation, and inflammation modulations for the treatment of OA is promising. MSCs migrate to injured sites, inhibit pro-inflammatory pathways, and promote tissue repair by releasing paracrine signals and differentiating into specialized chondrocytes. Multiple clinical trials have displayed a significant improvement in both pain and joint function, inflammatory cell reduction within a joint, and articular cartilage growth as well as patient safety. However, high quality evidence supporting the beneficial role of MSCs is lacking due to the limited number of studies, small populations tested, and the use of various derivatives. Although limited, current evidence suggests MSCs are a potential therapeutic in OA and provides a great foundation for further research.
描述并讨论间充质干细胞(MSCs)的假定机制及其作为骨关节炎(OA)潜在治疗方法的作用。
OA是一种慢性退行性关节疾病,影响着全球数百万人。传统治疗方法,包括物理治疗、抗炎药、关节内注射和外科手术,旨在控制症状而非改变病情。鉴于人们更好地理解了低度炎症会破坏OA中的关节软骨稳态,作为一种再生医学形式的MSCs应用应运而生,其目标是缓解症状并逆转OA中出现的关节软骨损伤。
使用2006年至2021年5月期间可用的搜索词“骨关节炎”“间充质干细胞”“再生医学”“软骨细胞”和“关节软骨”对PubMed进行检索。
通过直接组织生长、分化和炎症调节使用MSC疗法治疗OA以实现关节软骨再生是有前景的。MSCs迁移到损伤部位,抑制促炎途径,并通过释放旁分泌信号和分化为特定软骨细胞来促进组织修复。多项临床试验显示,在疼痛和关节功能、关节内炎症细胞减少、关节软骨生长以及患者安全性方面均有显著改善。然而,由于研究数量有限、测试人群规模小以及使用了各种衍生物,缺乏支持MSCs有益作用的高质量证据。尽管有限,但目前的证据表明MSCs是OA的一种潜在治疗方法,并为进一步研究提供了良好的基础。